Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.50    0.50 (0.71%)
Bid:
70.00
Ask:
71.00
Spread: 1.00 (1.429%)
Market Cap: £320.85m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Board Appointment

23 Dec 2013 07:00

RNS Number : 1772W
Avacta Group PLC
23 December 2013
 



 

 

 

Avacta Group plc

("Avacta" or the "Group")

 

Craig Slater joins the Board of Avacta Group plc as Chief Operating Officer

 

Avacta Group plc, the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, is pleased to announce that Craig Slater has joined the Board as Chief Operating Officer with immediate effect.

 

Mr Slater has more than 25 years experience of commercial, operational and group management roles in specialist engineering, construction, software and marketing groups. More specifically this experience includes the supply of specialist equipment to Life Science clients, B2B service provision and the implementation of growth plans in SME businesses. Mr Slater has been working with Avacta since June 2012, primarily in a commercial and operational capacity within Avacta Analytical and latterly within Avacta Animal Health.

 

Commenting on the appointment, Alastair Smith, Chief Executive of Avacta said: "The Board is delighted that Craig is joining the Group as Chief Operating Officer. We have already benefited greatly from his experience since he joined us in 2012 and his operational and strategic input will be invaluable in the future."

 

Mr Slater, aged 50, is a director/partner or has been a director/partner of the following companies/partnerships during the previous five years:

 

Current Directorships

Veracito Limited

QPC Holdings Limited

Adapt Formwork Holdings Limited

Adapt Formwork Limited

Gateway 3D Limited

Sitedesk Limited

 

Previous Directorships (in last 5 years)

Eleco Public Limited Company

Bell & Webster Concrete Limited

Milbury Systems Limited

Eleco (Pp) Limited

Eleco (Dcs) Limited

Eleco (Spp) Limited

Eleco (Gns) Limited

Eleco (Sd) Limited

CORGI Group Limited

Corgi Gas Registration Limited

Corgi Services Limited

Altitude Group Plc

Adproducts.com Limited

Advertising Gifts Limited

Advertising Gifts.net Limited

Boxcam Limited

Brand Logistics Limited

Business Gifts Limited

Corporate Gifts Limited

Corporate Solutions (UK) Limited

Distinctive Ideas Limited

Dowlis Corporate Solutions (UK) Limited

Promoserve Business Systems Limited

Promotional Gifts Limited

Promotional Items Limited

Promotional Merchandise Limited

Promotional Store Limited

Ross Promotional Products Limited

Silent Kite Limited

The Advertising Products Group Limited

The Bentley Collection Limited

Touchpaper Communications Limited

Trade Only Limited

 

Mr Slater does not hold any ordinary shares, or options over ordinary shares, in the Company.

 

Save for the information disclosed above there is no other information to be disclosed on Mr Slater under Schedule 2(g) of the AIM Rules.

 

- Ends -

 

Enquiries:

 

Avacta Group plc

www.avacta.com

Alastair Smith, Chief Executive Officer

Tel: +44 (0) 844 414 0452

Tim Sykes, Chief Financial Officer

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

 

James Black (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Mike Wort

Mob: +44 (0)7900 608 002

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFEWFFFFDSELE
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.